SAR by (Protein-Observed) ¹⁹F NMR.

ABSTRACT: Inhibitor discovery for protein-protein interactions has proven difficult due to the large protein surface areas and dynamic interfaces involved. This is particularly the case when targeting transcription-factor-protein interactions. To address this challenge, structural biology approaches for ligand discovery using X-ray crystallography, mass spectrometry, and nuclear magnetic resonance (NMR) spectroscopy have had a significant impact on advancing small molecule inhibitors into the clinic, including the U.S. Food and Drug Administration approved drug, Venetoclax. Inspired by the protein-observed NMR approach using ¹H-¹⁵N-HSQC NMR which detects chemical shift perturbations of ¹⁵N-labeled amides, we have applied a complementary protein-observed ¹⁹F NMR approach using ¹⁹F-labeled side-chains that are enriched at protein-protein-interaction interfaces. This protein-observed ¹⁹F NMR assay is abbreviated PrOF NMR to distinguish the experiment from the more commonly employed ligand-observed ¹⁹F NMR methods. In this Account, we describe our efforts using PrOF NMR as a ligand discovery tool, particularly for fragment-based ligand discovery (FBLD). We metabolically label the aromatic amino acids on proteins due to the enrichment of aromatic residues at protein interfaces. We choose the ¹⁹F nucleus due to its high signal sensitivity and the hyperresponsiveness of ¹⁹F to changes in chemical environment. Simultaneous labeling with two different types of fluorinated aromatic amino acids for PrOF NMR has also been achieved. We first describe the technical aspects of considering the application of PrOF NMR for characterizing native protein-protein interactions and for ligand screening. Several test cases are further described with a focus on a transcription factor coactivator interaction with the KIX domain of CBP/p300 and two epigenetic regulatory domains, the bromodomains of BRD4 and BPTF. Through these case studies, we highlight medicinal chemistry applications in FBLD, selectivity screens, structure-activity relationship (SAR) studies, and ligand deconstruction approaches. These studies have led to the discovery of some of the first inhibitors for BPTF and a novel inhibitor class for the N-terminal bromodomain of BRD4. The speed, ease of interpretation, and relatively low concentration of protein needed for NMR-based binding experiments affords a rapid, structural biology-based method to discover and characterize both native and new ligands for bromodomains, and it may find utility in the study of additional epigenetic proteins and transcription-factor-protein interactions.

SUBMITTER: Divakaran A 

PROVIDER: S-EPMC8117411 | biostudies-literature |

REPOSITORIES: biostudies-literature